Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 1Phase 1 1

Status

Active not recruiting 6Terminated 5Completed 4Recruiting 2Withdrawn 1Available 1

Sponsor Class

INDUSTRY 6OTHER 1NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 5Sarcoma 1

Conditions

Multiple Myeloma 5Desmoid Tumors 1

Interventions

pembrolizumab 184Carboplatin 132Paclitaxel 101Cisplatin 101Gemcitabine 86Pemetrexed 79durvalumab 75Nivolumab 66Docetaxel 56atezolizumab 52Bevacizumab 50Cyclophosphamide 49Dexamethasone 45Capecitabine 45Oxaliplatin 43130-nm albumin-bound paclitaxel 41Rituximab 40Fulvestrant 39Lenalidomide 38Fluorouracil 38Prednisone 32osimertinib 31olaparib 29Leucovorin 29venetoclax 28fludarabine 28Trastuzumab 27Doxorubicin 27Etoposide 25Cetuximab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × nirogacestat × Clear all
NCT04722146 2026-06-05

MajesTEC-2

Janssen Research & Development, LLC

Phase 1 Active not recruiting
140 enrolled
Plasma cell

Multiple Myeloma

NCT07170644 2026-05-08

A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 2 Active not recruiting
20 enrolled
Sarcoma

Desmoid Tumors

NCT04126200 2026-05-06

DREAMM 5

GlaxoSmithKline

Phase 1/2 Active not recruiting
208 enrolled 5 charts
Plasma cell

Multiple Myeloma

NCT07084896 2026-05-06

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM

GlaxoSmithKline

Phase 1/2 Active not recruiting
106 enrolled 32 charts
Plasma cell

Multiple Myeloma

NCT07150091 2025-09-02

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM

GlaxoSmithKline

Phase 1/2 Active not recruiting
20 enrolled
Plasma cell

Multiple Myeloma

NCT07150104 2025-09-02

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM

GlaxoSmithKline

Phase 1/2 Active not recruiting
14 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡